- Veru Inc (NASDAQ: VERU) has submitted a 505(b)(2) New Drug Application with the FDA for TADFIN (tadalafil 5mg and finasteride 5mg) capsules, daily oral dosing combination formulation, for the treatment of benign prostatic hyperplasia (BPH), also called prostate gland enlargement.
- The agency's goal date is expected in December 2021.
- TADFIN revenues will be part of Veru's sexual health commercial business.
- Eli Lily and Co's (NYSE: LLY) CIALIS (tadalafil) is currently approved for the treatment of BPH and erectile dysfunction, and Merck & Co Inc's (NYSE: MRK) MPROSCAR (finasteride) is approved for male pattern hair loss (androgenic alopecia).
- The company's stock rallied after it announced positive efficacy and safety results from a Phase 2 trial evaluating VERU-111 versus placebo in approximately 40 hospitalized patients at high risk for Acute Respiratory Distress Syndrome from SARS-CoV-2.
- Price Action: VERU is down 6.9% at $15.3 on the last check Tuesday.
Veru Files US Application For TADFIN Combo For Prostate Enlargement
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.